TEVA PHARMACEUTICAL INDUSTRIES LTD

For the period ended Jun 30, 2025. Filed Jul 30, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Jul 30, 2025

TEVA$42.61+2.0%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated statements of changes in equity

	Teva shareholders’ equity
	Ordinary shares
	Number ofshares (inmillions)	Statedvalue	Additionalpaid-in capital	Retainedearnings(accumulateddeficit)	Accumulated othercomprehensive(loss)	Treasuryshares	Total Tevashareholders’equity	Non-controllinginterests	Total equity
(U.S. dollars in millions)
Balance at March 31, 2025	1,253	58	27,965	(14,958)	(2,675)	(4,128)	6,262	7	6,269
Net Income (loss)				282			282	*	283
Other comprehensive income (loss)					244		244		244
Stock-based compensation expense			38				38		38
Balance at June 30, 2025	1,253	$58	$28,003	$(14,676)	$(2,431)	$(4,128)	$6,827	$7	$6,834

*	Represents an amount less than $0.5 million.

	Teva shareholders’ equity
	Ordinary shares
	Number ofshares (inmillions)	Statedvalue	Additionalpaid-in capital	Retainedearnings(accumulateddeficit)	Accumulated othercomprehensive(loss)	Treasuryshares	Total Tevashareholders’equity	Non-controllinginterests	Total equity
(U.S. dollars in millions)
Balance at December 31, 2024	1,240	58	27,764	(15,173)	(3,148)	(4,128)	5,373	7	5,380
Net Income (loss)				497			497	*	497
Other comprehensive income (loss)					717		717		717
Issuance of Shares	13	*					*		*
Proceeds from exercise of options			3				3		3
Stock-based compensation expense			72				72		72
Purchase of shares from redeemable non-controlling interests**			165				165		165
Balance at June 30, 2025	1,253	$58	$28,003	$(14,676)	$(2,431)	$(4,128)	$6,827	$7	$6,834

*	Represents an amount less than $0.5 million.

**	In connection with the sale of Teva’s business venture in Japan. See note 17.

	Teva shareholders’ equity
	Ordinary shares
	Number ofshares (inmillions)	Statedvalue	Additionalpaid-in capital	Retainedearnings(accumulateddeficit)	Accumulated othercomprehensive(loss)	Treasuryshares	Total Tevashareholders’equity	Non-controllinginterests	Total equity
(U.S. dollars in millions)
Balance at March 31, 2024	1,238	58	27,796	(13,673)	(2,775)	(4,128)	7,278	265	7,543
Net Income (loss)				(846)			(846)	(29)	(874)
Other comprehensive income (loss)					(106)		(106)	(32)	(138)
Issuance of shares	*	*					*		*
Stock-based compensation expense			32				32		32
Balance at June 30, 2024	1,239	$58	$27,829	$(14,519)	$(2,881)	$(4,128)	$6,359	$204	$6,563

*	Represents an amount less than 0.5 million.

	Teva shareholders’ equity
	Ordinary shares
	Number ofshares (inmillions)	Statedvalue	Additionalpaid-in capital	Retainedearnings(accumulateddeficit)	Accumulated othercomprehensive(loss)	Treasuryshares	Total Tevashareholders’equity	Non-controllinginterests	Total equity
(U.S. dollars in millions)
Balance at December 31, 2023	1,227	57	27,807	(13,534)	(2,697)	(4,128)	7,506	620	8,126
Net Income (loss)				(985)			(985)	(309)	(1,294)
Other comprehensive income (loss)					(181)		(181)	(74)	(255)
Issuance of Shares	12	1	*				1		1
Stock-based compensation expense			60				60		60
Proceeds from exercise of options			6				6		6
Dividend to non-controlling interest **								(18)	(18)
Purchase of shares from non-controlling interests***			(45)		(3)		(48)	(16)	(64)
Balance at June 30, 2024	1,239	$58	$27,829	$(14,519)	$(2,881)	$(4,128)	$6,359	$204	$6,563

*	Represents an amount less than $0.5 million.

**	In connection with dividends to non-controlling interests in Teva’s business venture in Japan.

***	Purchase of shares from non-controlling interests in a Teva’s subsidiary in Switzerland.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.